EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Phenotype Spectrum of TRPM3 ‐Associated Disorders

Laura Jolitz iD, Ingo Helbig iD, Mark P Fitzgerald, Sarah McKeown Ruggiero, Stacey Cohen, Chloe Angelini, Elena Vallespin, Vincent Michaud, Anna Gerasimenko, Benjamin Cogne, Bertrand Isidor, Boris Keren und 12 weitere

Annals of Neurology · 2025-03 · 97 (3) · 561-570

DOI: 10.1002/ana.27141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 03.01.2025. Verfasst von Laura Jolitz und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany. Hauptthemen laut MEDLINE: TRPM Cation Channels, Epilepsy, Intellectual Disability, Developmental Disabilities. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Einstein Stiftung Fellowship through the Günter Endres Fund, Deutsche Forschungsgemeinschaft, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Monoallelic variants in the transient receptor potential melastatin‐related type 3 gene ( TRPM3 ) have been associated with neurodevelopmental manifestations, but knowledge on the clinical manifestations and treatment options is limited. We characterized the clinical spectrum, highlighting particularly the epilepsy phenotype, and the effect of treatments.

Methods

We analyzed retrospectively the phenotypes and genotypes of 43 individuals with TRPM3 variants, acquired from GeneMatcher and collaborations (n = 21), and through a systematic literature search (n = 22). We included all patients with a pathogenic TRPM3 variant.

Results

The median age at the time of the study was 10 years, with a preponderance of girls (60%) versus boys (40%). Frequent findings were developmental delay and/or intellectual disability (93%), global or axial hypotonia (77%), ocular involvement (70%), musculoskeletal anomalies (65%), and dysmorphic features (58%). Epilepsy was diagnosed in 31 patients (72%), classified in all as developmental and epileptic encephalopathy with or without spike wave activation in sleep (DEE/DEE‐SWAS). Patients with the variant p.Val1002Met (n = 24) significantly more often had developmental delay and epilepsy. The most effective anti‐seizure medication was primidone. All treated patients showed an improvement in seizure frequency, motor and speech development, and/or learning capability with this drug.

Interpretation

Developmental delay/intellectual disability and epilepsy are dominant phenotypic features in patients with TRPM3 variants. Given that epilepsy can negatively impact development, screening for awake and sleep electroencephalogram abnormalities and other manifestations are essential to offer early intervention. The TRPM3 channel blocker primidone has shown promising effects and should be considered in every child with a TRPM3 gain‐of‐function variant. ANN NEUROL 2025;97:561–570

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TRPM Cation ChannelsEpilepsyIntellectual DisabilityDevelopmental DisabilitiesHumansFemaleMaleChildPhenotypeChild, PreschoolAdolescentRetrospective StudiesInfantYoung AdultAdult

Substanzen

TRPM Cation ChannelsTRPM3 protein, human

Autor:innen und Institutionen

  • Department of Pediatric Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Center for Chronically Sick Children, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Institute for Cell Biology and Neurobiology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Section CNS Development and Neurologic Disease, German Center for Child and Adolescent Health (DZKJ), partner site Berlin, Germany.
  • Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

ORCID-Profile: Laura Jolitz, Ingo Helbig, David Dyment, Lena-Luise Becker, Angela M Kaindl

Förderung

  • Einstein Stiftung Fellowship through the Günter Endres Fund
  • Deutsche Forschungsgemeinschaft
  • NINDS NIH HHS
  • German Center for Child and Adolescent Health (DZKJ)

Zitieren

APA

Jolitz, L., Helbig, I., Fitzgerald, M. P., McKeown Ruggiero, S., Cohen, S., Angelini, C., Vallespin, E., Michaud, V., Gerasimenko, A., Cogne, B., Isidor, B., Keren, B., Dyment, D., Heron, D., Karstensen, H. G., Cuppen, I., Christodoulou, J., Wilson, M., Lake, N. J., …, & Kaindl, A. M. (2025). Phenotype Spectrum of TRPM3 ‐Associated Disorders. Annals of Neurology, 97(3), 561-570. https://doi.org/10.1002/ana.27141

Vancouver

Jolitz L, Helbig I, Fitzgerald MP, McKeown Ruggiero S, Cohen S, Angelini C, et al. Phenotype Spectrum of TRPM3 ‐Associated Disorders. Annals of Neurology. 2025;97(3):561-570. doi:10.1002/ana.27141

BibTeX
@article{Jolitz2025,
  author = {Jolitz, Laura and Helbig, Ingo and Fitzgerald, Mark P and McKeown Ruggiero, Sarah and Cohen, Stacey and Angelini, Chloe and Vallespin, Elena and Michaud, Vincent and Gerasimenko, Anna and Cogne, Benjamin and Isidor, Bertrand and Keren, Boris and Dyment, David and Heron, Delphine and Karstensen, Helena Gásdal and Cuppen, Inge and Christodoulou, John and Wilson, Meredith and Lake, Nicole J and Biskup, Saskia and Syrbe, Steffen and Mori, Takayasu and Becker, Lena-Luise and Kaindl, Angela M},
  title = {Phenotype Spectrum of TRPM3 ‐Associated Disorders},
  journal = {Annals of Neurology},
  year = {2025},
  volume = {97},
  number = {3},
  pages = {561--570},
  doi = {10.1002/ana.27141}
}
Kostenlos starten →